When AI chatbots give bad health advice, no one can see the damage - Binghamton University
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
As more and more people turn to AI chatbots for quick, 24/7 medical advice, a new perspective paper co-authored by faculty at Binghamton University explores the risks this practice carries that are largely invisible to users – and healthcare systems. The paper, written by researchers at Binghamton University, Stanford University, Texas A&M University, and Indiana University, and published in Nature Health, examines what happens when a chatbot gives someone bad health advice. The authors argue that the harm is hard to catch because the conversation stays on the AI company's platform, the person has no place to report the problem, and outside researchers cannot measure the damage. “We’re getting medical advice from these chatbots, but nobody—literally no one—is looking at this. If there’s an error or an issue, there’s just no way for people to know,” said Kaicheng Yang, an assistant professor in the School of Computing at Binghamton University’s Thomas J. Watson College of Engineering and Applied Science and one of the paper’s authors. The researchers gave the example of a 60-year-old man who asked ChatGPT how to cut chloride from his diet and swapped table salt with sodium bromide.
This article is an excerpt. To read the full content, visit the original source. Binghamton University
Related articles
How do chatbots affect your mental health? - Université de Montréal
“How are you doing?” “Are you sleeping well?” “Do you drink?” These are typical opening questions a mental-health professional might ask a patient. Soon, another question may be added to the list: “How do you use artificial intelligence (AI)?”
Bioengineer.org | Viral blips during HIV therapy are common and rarely signal treatment failure, Swedish study finds - European AIDS Treatment Group
Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.
0 comments
No comments yet. Be the first to share your thoughts!